You are here

Funding

CFAR Grants

See Current Funding Opportunities - April 16, 2018

 

Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle- Income Countries (R21 Clinical Trial Optional)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), Fogarty International Center (FIC), National Institute of Mental Health (NIMH), National Cancer Institute (NCI), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Office of Behavioral and Social Sciences Research (OBSSR)
  • Purpose: The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support research on a) novel stigma reduction interventions that link to increase in care-seeking behavior and/or decrease in transmission; b) reducing the impact of stigma on adolescent and/or youth health; c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections; d) reducing effects of stigma on and/or by family members or caregivers of PLWH; and e) innovative and improved stigma measurement in the context of implementation of an intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to initiate exploratory studies to determine the feasibility of stigma interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).
  • Open Date: July 1, 2018
  • Amount of Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
  • Due Date: August 1, 2018 by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-18-732.html
  • End Date: August 2, 2018

 

High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)

 

Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R01 Clinical Trial Optional)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  • Purpose: HIV+ alcohol users remain at high risk for medication non-adherence and rapid disease progression, medication toxicities, organ failure, and poor viremic control, leading to increased risk of transmission and premature death. Recent advances in technology and biomedical science (e.g., new pharmacological agents, alcohol and inflammation biomarkers, internet and mobile technology) open new opportunities for strengthening the quality of HIV/alcohol-related implementation research through utilization of novel technology and biomarkers. This initiative seeks to advance knowledge on implementation and comparative effectiveness of alcohol-focused interventions among HIV+ individuals. Multiple factors need to be investigated, including potentially important patient and provider characteristics, and the organizational, financial, and structural factors that facilitate or inhibit the delivery of evidence-based services for HIV+ individuals with a range of severity of alcohol use problems. The overall goal is to inform clinical decision-making to implement effective interventions that will improve prevention, care, and outcomes across the continuum of HIV and alcohol problem severity and patterns of alcohol use. This solicitation is divided into two major topics. An application may choose to address one or both. These topics include: 1) comparative effectiveness research focused on understanding factors related to early detection, patient engagement and retention in appropriate alcohol and HIV care, and achieving and maintaining optimal treatment responses in diverse settings, and 2) modeling and testing alternative implementation approaches to improve uptake and scaling-up of effective interventions and reduce HIV disease transmission and progression.
  • Open Date: January 5, 2018
  • Amount of Award: NIH intends to fund an estimate of 4-6 awards, corresponding to a total of $3 million per year, for fiscal year 2018 to 2022.
  • Due Date: Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. 
    Standard AIDS dates apply), by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAS-18-557.html
  • End Date: May 8, 2020

 

Detection of HIV for Self-Testing (R61/R33)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support bi-phasic developmental, discovery-driven, or hypothesis-driven research focused on innovative strategies to detect HIV either within the first two weeks of infection or to monitor viral rebound after stopping or developing resistance to antiretroviral therapy. Applications should propose simple diagnostic tools that would be feasible for a self-testing platform to allow untrained individuals to detect HIV. Interdisciplinary collaborations that include biomedical, physical, and behavioral sciences are highly encouraged.    
  • Open Date: November 6, 2017
  • Amount of Award: NIAID intends to commit $2,640,000 in FY 2018 to fund 3-6 awards. NIMH intends to commit $300,000 total cost in FY 2018.  Future year amounts will depend on annual appropriations. 
  • Due Date: December 6, 2017, December 6, 2018, and December 6, 2019 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
    December 6, 2017, December 6, 2018, and December 6, 2019, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-17-471.html
  • End Date: December 7, 2019

 

HIV/AIDS and the Tumor Niche (R01)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Cancer Institute (NCI)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, diagnosis, and treatment of cancer observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS).
  • Open Date: July 7, 2017
  • Amount of Award: NIH intends to fund an estimate of 4-5 awards, corresponding to a total of $2,000,000, for fiscal years 2018 and 2019. Future year amounts will depend on annual appropriations.
  • Due Date: August 7, 2017; August 7, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
    August 7, 2017; August 7, 2018. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-030.html
  • End Date: August 8, 2018

 

Phylodynamic Tracking of HIV Transmission (R01)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support interdisciplinary research collaborations to study and optimize approaches using phylodynamic analyses of HIV genotyping databases to monitor HIV transmission networks in near real-time. The long-range goal is to leverage existing databases and support innovations in HIV phylodynamics to better inform testing, treatment, and prevention efforts. 
  • Open Date: February 15, 2017 
  • Amount of Award: NIH intends to fund an estimate of 4-7 awards, corresponding to a total of $4.39 M, for fiscal year 2018. Future year amounts will depend on annual appropriations.
  • Due Date: March 15, 2017; March 15, 2018; March 15, 2019  , by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates.
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-17-048.html
  • End Date: March 16, 2019

 

"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR)
  • Purpose: The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals. 
    This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.
    This FOA encourages research efforts that will (i) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers and (ii) provide information on the clinical outcomes of such cancers in the HIV-infected population. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.   
  • Open Date: December 7, 2016
  • Amount of Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
  • Due Date: January 7, 2017
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PA-16-426.html
  • End Date: September 8, 2019

 

"High" or "Medium" Priority AIDS Research  on Non-AIDS-defining or AIDS-defining Cancers (R21)

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR)
  • Purpose: The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.  
    This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection. 
    This FOA encourages research efforts that will (i) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers and (ii) provide information on the clinical outcomes of such cancers in the HIV-infected population. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.   
  • Open Date: December 7, 2016
  • Amount of Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
  • Due Date: January 7, 2017
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PA-16-425.html
  • End Date: September 8, 2019

 

Apply now for the UCSF CAPS Visiting Professors Program

The UCSF Center for AIDS Prevention Studies (CAPS) has a Visiting Professors program to train investigators in conducting research with ethnic minority communities. The VP Program is designed to assist investigators already conducting HIV-prevention research with minority communities to improve their programs of research and obtain additional funding for their work. It includes a 6-week summer residency, pilot funding, and other mentorship and career development opportunities. More information is described below and at their website: http://vp.ucsf.edu/.